Amarin just turned in Q3 2026 results that flipped a long running story. After a year of losses, the biotech posted a small profit of US$0.245 million and delivered its fourth straight quarter of positive operating cash flow. Yet the stock barely moved, slipping about 0.1% on the day.
That muted reaction sits at odds with the emotional overhang around an unprofitable past. Traders focused on soft top line revenue of US$39.6 million. The more important shift was psychological, as this report put profitability and cash generation back on the table.
Love that Amarin is back to modest profit with four straight quarters of positive operating cash flow, but uneasy about the fragile revenue base. Compare this turnaround story with companies that already pair stronger sales with cleaner balance sheets in our list of solid balance sheet and fundamentals stocks (22 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):US$39.55 million vs. US$49.67 million (top line declined about 20%)
-
Net Income (Q3 2026 vs Q3 2025):US$0.245 million profit vs. a loss of US$7.738 million (moved from loss to roughly break even)
-
Basic EPS (Q3 2026 vs Q3 2025):US$0.0117 per share vs. a loss of US$0.3724 per share (shifted from loss per share to a small profit)
-
Trailing 12-Month Net Income (TTM to Q3 2026 vs TTM to Q3 2025):loss of US$19.141 million vs. loss of US$103.588 million (full year loss narrowed materially)
A failed primary endpoint still came with a survival surprise. Ask Charlie what the EMT2 cancer signal could mean for Amarin .
Amarin bull case leans on international engine
Optimists argue that Amarin's future hinges on partners turning strong demand into a durable overseas growth engine.
"International expansion is gaining momentum with double• or triple-digit demand growth reported in Europe, China (68% sequential growth), Australia (75% Q/Q growth), Canada, Middle East & North Africa (62% Q/Q growth), and regulatory approvals expanding to fifty markets globally, indicating global secular tailwinds that could stabilize or grow overall company revenues despite U.S. headwinds."
Q3 shows some of that thesis translating into financials. Ex U.S. demand looks strong and licensing and royalty revenue reached US$2.7 million. Yet total net revenue still fell year over year to US$39.6 million, so partner-led momentum has not yet fully offset U.S. pricing pressure.
Bear case tests single product and model risk
Skeptics focus on whether product concentration and a royalty tilt keep earnings volatile even as Amarin cleans up operations.
"The focus on a single product (Vascepa) with limited pipeline diversification exposes Amarin to significant long-term earnings volatility and heightened risk if scientific, clinical, market, or regulatory setbacks occur, which can erode value faster amid accelerated global uptake of generics and biosimilars."
Q3 underlines that exposure. Almost all revenue still comes from icosapent ethyl, while U.S. product sales declined to US$28.5 million in the face of generic pressure. The firm did reach slight profitability and four straight quarters of positive operating cash flow, but earnings still lean heavily on one therapy and on partner execution.
Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there .
Hunt Mispriced Earnings Stories
Amarin shows how sentiment can shift after financial results reveal a change. The real opportunity sits in finding stocks that could be undervalued before the market adjusts.
-
Company 1 - 43% below our estimate - turn a swelling backlog of tech heavy buildouts into recurring installation, retrofit and remote monitoring work.
-
Company 2 - 36% below our estimate - use government trade in subsidies and growing recommerce acceptance to pull more used devices into its refurbishment platform.
-
Company 3 - 49% below our estimate - run a high share financial and shopping super app while testing whether its bundled model can replicate in a new market.
Those are three of them. See the full list of 30 companies trading below our fair value estimates →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AMRN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
